Skip to main content

Table 3 Summary of current TBK1 inhibitors

From: The role of TBK1 in cancer pathogenesis and anticancer immunity

Compounds

Targets

Reference

Clinical Trial

Amlexanox (AMX)

TBK1/IKKε

[40, 246,247,248,249,250,251,252]

NCT01842282; NCT01975935

AZ13102909 (AZ909)

TBK1

[223]

 

BAY-985

TBK1/IKKε

[253]

 

BX795

TBK1/IKKε

Aurora B

NUAK1

PDK1

[254,255,256]

 

Compound I

TBK1/IKKε

[244]

 

Compound II

TBK1/IKKε

[229, 257]

 

DMX-14

TBK1/IKKε

[258]

 

GSK8612

TBK1

[259]

 

MDK10496

TBK1/IKKε

[260]

 

MMB/CYT387/GS-0387

TBK1/IKKε

ACVR1

ALK2

JAK1/2

[231, 261,262,263,264,265,266,267]

NCT02101021; NCT02206763; NCT02258607; NCT04173494/MOMENTUM; NCT01969838/SIMPLIFY1; NCT02101268

MPI-0485520

TBK1/IKKε

[268]

 

MRT67307

TBK1/IKKε

ULK1/2

[99]

 

MRT68601

TBK1

[255]

 

UNC6587/Cereblon-TBK1 PROTAC

TBK1

[81]

 

15a

TBK1/IKKε

Aurora A

GSK3β

Aurora A

PDK1

[269]

 

200A

TBK1/IKKε

[270]

 

3i/pVHL-TBK1 PROTAC

TBK1

[271]

Â